Core Insights - Inspira Technologies has reaffirmed binding purchase orders totaling $49.5 million, with payment activities expected to commence in the 2026 fiscal cycle, aligning with regulatory and deployment milestones [1][2]. Group 1: Purchase Orders and Revenue Recognition - The company confirmed that the purchase orders remain valid and that the distributor plans to advance these orders toward execution in 2026 [2]. - The payment framework for the binding purchase orders is structured to align with the company's revenue recognition framework, which is set to begin in the 2026 fiscal cycle [2][4]. Group 2: Execution and Coordination - The updated schedule for execution reflects necessary regulatory sequencing, technical implementation requirements, and coordination with institutional capital allocations for deliveries [3]. - Inspira is actively coordinating with distribution partners, regulators, and funding organizations to advance execution milestones and finalize delivery schedules, aiming to reduce execution risk and enhance operational visibility [4]. Group 3: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [5]. - The company is developing the INSPIRA ART500 system for oxygenation while patients remain awake and is advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [5].

Core Viewpoint - The article discusses the release of the procurement document for high-value medical consumables, specifically drug-coated balloons and urological intervention materials, by the National Organization for High-Value Medical Consumables Joint Procurement Office, outlining the requirements and timelines for the sixth batch of centralized procurement [4]. Group 1: Procurement Details - The procurement cycle will run from the effective date until December 31, 2028, with products needing to obtain valid medical device registration certificates by December 26, 2025 [4]. - The procurement covers two main categories: drug-coated balloons and urological intervention materials, with a total annual demand exceeding 3.4 million sets across 12 subcategories [4]. - The procurement will be implemented by the Tianjin Pharmaceutical Procurement Center, which will handle daily operations [4]. Group 2: Product Categories and Demand - The drug-coated balloon category includes four subcategories, with an annual demand of 690,000 units, where the coronary drug-coated balloon has the highest demand at 614,800 units [9]. - Major domestic companies such as Yinyi Biological, Lepu Medical, and Shenqi Medical lead in demand for coronary drug-coated balloons, with respective demands of 113,300, 97,100, and 86,900 units [9]. - The urological intervention category focuses on key surgical pathways, with an annual demand exceeding 2.75 million sets, where the ureteral intervention guide wire is the largest single item with a demand of 1,372,400 units [9]. Group 3: Market Share and Domestic Replacement - In the procurement, domestic companies account for approximately 80% of the market share for both coronary and peripheral drug-coated balloons, while foreign companies hold about 20% [10]. - The demand for ureteral intervention guide wires is also dominated by domestic products, indicating a trend towards accelerated domestic replacement [10]. - The introduction of the "anchor price" concept aims to rationalize prices and reduce vicious competition in the industry, benefiting more patients [7][19]. Group 4: Pricing and Competitive Rules - The procurement document introduces an "anchor price" based on the arithmetic average of the effective bidding prices of participating companies, set at 65% of the average price [19]. - The maximum effective bidding prices for various products have been established, with significant reductions compared to previous prices, such as the maximum effective bidding price for a non-target pressure measurement ureteral soft mirror being set at 1,860 yuan [11]. - The rules for selection and competition have been optimized, allowing non-selected companies to adjust their bids for a chance to qualify, which may enhance participation rates [20]. Group 5: Industry Impact - The changes in procurement rules are expected to reshape the competitive landscape, with leading domestic companies likely to benefit the most, while foreign companies may face pressure to localize [20]. - Smaller companies may exit the market, leading to increased industry concentration [22].

Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

Core Viewpoint - CooperCompanies has appointed Walter (Walt) M Rosebrough, Jr. as an independent director and entered into a cooperation agreement with Browning West, aiming to enhance governance and drive long-term value for shareholders [1][3]. Group 1: Appointment and Governance - Walter Rosebrough will join the Board's Corporate Governance & Nominating Committee and is being considered for the Chair position by the end of 2026 [1]. - The Board will also appoint a new independent director with medical technology experience, in agreement with Browning West [1]. Group 2: Background of Walter Rosebrough - Rosebrough served as CEO of STERIS from 2007 to 2021, achieving a 10-fold total return on stock and an 18% annualized return, compared to a 10% annualized return for the S&P 500 [2]. - His career includes nearly two decades at Hill-Rom Holdings, where he held senior executive roles [2]. Group 3: Strategic Vision and Cooperation - Colleen Jay, the Incoming Chair of the Board, emphasized Rosebrough's leadership experience and track record in supporting sustainable growth [3]. - Browning West expressed confidence in Cooper's long-term potential and the constructive path forward with the Board [3]. - Browning West has agreed to customary standstill and voting commitments and will support the Board's full slate of directors at the 2026 Annual Meeting [3]. Group 4: Company Overview - CooperCompanies is a global medical device company with two business units: CooperVision and CooperSurgical, impacting over fifty million lives annually [4]. - The company is headquartered in San Ramon, CA, employs over 15,000 people, and sells products in over 130 countries [4]. Group 5: About Browning West - Browning West is an independent investment partnership focused on long-term value creation in high-quality businesses, primarily in North America and Western Europe [5]. - Founded in 2019, it is backed by leading foundations, family offices, and university endowments [5].

Core Viewpoint - Profound Medical Corp. has successfully closed a registered direct offering of 5,142,870 common shares at a price of $7.00 per share, generating approximately $36 million in gross proceeds before fees and expenses [1][3]. Financing Details - The offering was structured as a straightforward equity investment with no warrant coverage, led by healthcare-dedicated investors alongside existing shareholders [2]. - The gross proceeds from the offering are intended for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes [3]. Placement Agent - Konik Capital Partners, LLC acted as the exclusive placement agent for the offering [4]. Regulatory Information - The offering was made under an effective shelf registration statement on Form S-3, declared effective by the SEC on December 4, 2025 [5]. Future Plans - In addition to the registered direct offering, the company plans to complete a private placement to certain Canadian purchasers, expected to close on or before December 30, 2025, subject to necessary approvals [7]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [8]. - The company is commercializing TULSA-PRO, a technology that combines real-time MRI, AI-enhanced planning, and ultrasound for prostate disease treatment [9]. - Profound is also marketing Sonalleve, a therapeutic platform for treating uterine fibroids and other conditions, which has received various regulatory approvals [10].

Company Overview - Intuitive Surgical, Inc. (ISRG) has a market cap of $205.2 billion and is recognized as the global leader in robotic-assisted, minimally invasive surgery, headquartered in Sunnyvale, California [1] Financial Performance - Analysts expect Intuitive Surgical to report an EPS of $1.83 for fiscal Q4 2025, which is a decrease of 5.2% from $1.93 in the same quarter last year [2] - For fiscal 2025, the anticipated EPS is $6.93, reflecting a 6.9% increase from $6.48 in fiscal 2024, with further growth expected to $7.79 in fiscal 2026, a 12.4% year-over-year increase [3] Stock Performance - Over the past 52 weeks, shares of Intuitive Surgical have increased by 10.6%, which is lower than the S&P 500 Index's gain of 16% and the Health Care Select Sector SPDR Fund's return of 12.5% during the same period [4] - On December 11, shares fell more than 1% after Citigroup downgraded the stock from "Buy" to "Neutral," indicating a more cautious outlook despite strong fundamentals [5] Analyst Ratings - The consensus view on ISRG stock is cautiously optimistic, with a "Moderate Buy" rating. Among 29 analysts, 18 recommend a "Strong Buy," 2 suggest a "Moderate Buy," 8 advise a "Hold," and 1 has a "Strong Sell" rating [6] - The average analyst price target for Intuitive Surgical is $614.04, suggesting a potential upside of 5.9% from current price levels [6]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products, particularly the G6 and G7 glucose monitoring devices, during the class period from July 26, 2024, to September 17, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased DexCom securities during the specified class period [2]. - Investors have until December 26, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices that were not approved by the FDA, which compromised their reliability and posed health risks to users [3]. - It is claimed that the enhancements to the G7 were overstated, and the company downplayed the severity of issues related to the devices, leading to increased regulatory scrutiny and potential legal repercussions [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for further details and assistance [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary launch steps, leading to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top in securities class action settlements, recovering hundreds of millions for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5]. - It is claimed that Integer misrepresented its EP devices as a long-term growth driver, leading to misleading positive statements about its business and operations [5].